VIDEO: ‘Rapid increase in novel therapies’ for follicular lymphoma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

You know, in 2023, we are very lucky to have such a rapid increase in novel therapies. So for follicular lymphoma, we've been taking care of these patients for decades, and whereas historically it's just different types of chemotherapy. Now we are very lucky to have chemotherapies, of course still radiotherapy, but also now some, I think, very provocative targeted therapies, epigenetic based therapies and I think most excitingly rapidly increasing new numbers of immunotherapies, CAR T-cells and bispecific antibodies. And the progress in the those latter types of therapies just over the last few years, incredible. And even over the last year, FDA approval of one bispecific antibody, Mosunetuzumab, targeting CD20 and CD3, and many other bispecific antibodies sort of in the pipeline. A couple of them approved for DLBCL recently, which may also lead to approvals for follicular lymphoma in the next couple of years, both as monotherapies and maybe even more excitingly as corporation into standards of care. So, standard chemo immunotherapies plus bispecific antibodies, and as I mentioned also CAR T therapies approved in the third line and probably increasing numbers of platforms of safer and maybe better CAR T therapies as well.